Opinion|Videos|January 3, 2025
Treatment Goals and Unmet Needs in R/R AML
Panelists discuss how achieving responses with second-line treatment options after venetoclax-based regimens remains challenging, and explore strategies for bridging therapy to allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients who relapse post venetoclax while also addressing the evolving management of patients following transplant.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Briefly comment on your clinical experience with the difficulty achieving responses with the currently available second line and beyond treatment options after patients are treated with venetoclax plus azacitidine (or decitabine).
- How do current therapies meet the needs of patients post-venetoclax failure?
- How often are you able to bring your patients to allo-HSCT once they relapse post venetoclax? How are utilizing the currently available R/R options as bridging therapy to allo-HSCT?
- How are you managing patients following a transplant? Do you see this changing in the future?
Advertisement
Related to this article
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
A gene expression test identified the first 3 years after childbirth as a potential window of higher biological risk in breast cancer.
A phase 2 study of neoadjuvant cemiplimab in HHI-naive BCC of the head and neck produced a 60.1% ORR and a 42.9% surgical benefit rate.
Peter E. Fecci, MD, PhD, discusses unmet needs in glioblastoma management and the early promise of CAR T-cell therapy in this disease.
An MD Anderson Cancer Center study identified a new link between immune cells and a copper-induced form of cell death called cuproptosis.
Early phase 2 data showed a median OS of 29.3 months with BPM31510 plus chemoradiation in an MGMT-unmethylated subgroup of treatment-naive glioblastoma.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
Advertisement
Advertisement
Trending on OncLive
1
Pembrolizumab Monotherapy Improves PFS vs Chemotherapy in Frontline dMMR Endometrial Cancer
2
CAR T-Cell Engineering Produces Early Efficacy Signals in Glioblastoma
3
Frontline Sac-TMT Plus Pembrolizumab Meets PFS End Point in PD-L1–Negative, Nonsquamous NSCLC
4
International Intel: A Glance at the Top Global Breast Cancer News From April-June 2026
5